Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin
- 1 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 40 (9) , 2127-2142
Abstract
Objective: Atherothrombosis occurs upon rupture of an atherosclerotic plaque and leads to the formation of a mural thrombus. Computational fluid dynamics and numerical models indicated that the mechanical stress applied to a thrombus increases dramatically as a thrombus grows, and that strong inter-platelet interactions are essential to maintain its stability. We investigated whether GPVI (glycoprotein VI)-mediated platelet activation helps to maintain thrombus stability by using real-time video-microscopy. Approach and Results: We showed that GPVI blockade with 2 distinct Fab fragments promoted efficient disaggregation of human thrombi preformed on collagen or on human atherosclerotic plaque material in the absence of thrombin. ACT017-induced disaggregation was achieved under arterial blood flow conditions, and its effect increased with wall shear rate. GPVI regulated platelet activation within a growing thrombus as evidenced by the loss in thrombus contraction when GPVI was blocked, and the absence of the disaggregating effect of an anti-GPVI agent when the thrombi were fully activated with soluble agonists. The GPVI-dependent thrombus stabilizing effect was further supported by the fact that inhibition of any of the 4 key immunoreceptor tyrosine-based motif signalling molecules, src-kinases, Syk, PI3Kβ, or phospholipase C, resulted in kinetics of thrombus disaggregation similar to ACT017. The absence of ACT017-induced disaggregation of thrombi from 2 afibrinogenemic patients suggests that the role of GPVI requires interaction with fibrinogen. Finally, platelet disaggregation of fibrin-rich thrombi was also promoted by ACT017 in combination with r-tPA (recombinant tissue plasminogen activator). Conclusions: This work identifies an unrecognized role for GPVI in maintaining thrombus stability and suggests that targeting GPVI could dissolve platelet aggregates with a poor fibrin content.Keywords
This publication has 38 references indexed in Scilit:
- An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean familiesJournal of Thrombosis and Haemostasis, 2013
- A Humanized Glycoprotein VI (GPVI) Mouse Model to Assess the Antithrombotic Efficacies of Anti-GPVI AgentsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Genetic and antibody‐induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl3‐induced thrombosisJournal of Thrombosis and Haemostasis, 2011
- GPIbα-vWF Rolling under Shear Stress Shows Differences between Type 2B and 2M von Willebrand DiseaseBiophysical Journal, 2011
- Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterizationJournal of Thrombosis and Haemostasis, 2009
- Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutationsBlood, 2009
- Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital modelJournal of Thrombosis and Haemostasis, 2009
- Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodesBlood Coagulation & Fibrinolysis, 2008
- Laminin stimulates spreading of platelets through integrin α6β1–dependent activation of GPVIBlood, 2006
- Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivoThe FASEB Journal, 2003